First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced CancerToshio Shimizu, Amita Patnaik, Leslie Smetzer et al.|Clinical Cancer Research|2012Cited by 432
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitorJohanna C. Bendell, Amita Patnaik|British Journal of Cancer|2017Cited by 132
Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid TumorsToshio Shimizu, Anthony W. Tolcher, Patricia LoRusso et al.|Clinical Cancer Research|2014Cited by 82
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.George A. Fisher, Amita Patnaik, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2020Cited by 53